<DOC>
	<DOC>NCT01662414</DOC>
	<brief_summary>This is a double-blind, placebo-controlled, Phase IV trial , comparing HMS 90® versus placebo (soy protein) as add-on (adjuvant) therapy in subjects with idiopathic Parkinson's Disease. The principal objective is to evaluate the changes in biomarkers of oxidative stress and,plasma amino acids, as well as improvement of clinical symptoms and brain function</brief_summary>
	<brief_title>Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Neurodegenerative Diseases</mesh_term>
	<mesh_term>Central Nervous System Diseases</mesh_term>
	<mesh_term>Parkinsonian Disorders</mesh_term>
	<mesh_term>Basal Ganglia Diseases</mesh_term>
	<criteria>1. Subjects with Idiopathic Parkinson's Disease 2. Subjects who are willing and able to participate in the trial and has provided written, informed consent. 1. Subjects who are allergic to Whey protein (HMS 90®). 2. Subjects who are treated with chemotherapy . 3. Subjects with any history of neurodegenerative diseases, e.g., Alzheimer's disease. 4. Subjects with history of diabetes. 4.5. Subjects with abnormal liver function test</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>